Skip to main content
. Author manuscript; available in PMC: 2015 Apr 28.
Published in final edited form as: Ann Intern Med. 2014 Oct 7;161(7):461–471. doi: 10.7326/M14-1084

Table 3.

Adverse Events ≥ Grade 2 Occurring in at Least 5% of Subjects in any Group

Treatment group
ATV/r RAL DRVr/r

Adverse Effect Grade Total (%) Grade Total (%) Grade Total (%)
2 3 4 2 3 4 2 3 4
Diarrhea 35 11 0 46 (7.6) 26 10 0 36 (6.0) 46 6 0 52 (8.6)
Nausea 36 8 1 45 (7.4) 21 12 0 33 (5.5) 29 12 0 41 (6.8)
Vomiting 22 7 1 30 (5.0) 15 9 0 24 (4.0) 21 11 0 32 (5.3)
Abdominal pain 13 17 1 31 (5.1) 6 10 1 17 (2.8) 13 14 2 29 (4.8)
Headache 23 10 2 35 (5.8) 35 7 0 42 (7.0) 30 12 2 44(7.3)
Pain in extremity 27 14 1 42 (6.9) 31 14 0 45 (7.5) 18 13 1 32 (5.3)
Arthralgia 17 8 0 25 (4.1) 17 4 1 22 (3.6) 13 14 1 28 (4.7)
Back pain 14 4 0 18 (3.0) 21 10 0 31 (5.1) 9 12 0 21 (3.5)
Fatigue 32 6 1 39 (6.4) 26 5 0 31 (5.1) 26 7 0 33 (5.5)
Cough 33 9 0 42 (6.9) 32 8 0 40 (6.6) 31 5 0 36 (6.0)
Dyspnea 16 9 1 26 (4.3) 16 12 0 28 (4.6) 8 14 1 23 (3.8)
Pyrexia 16 9 1 26 (4.3) 25 10 0 35 (5.8) 18 7 2 27(4.5)
Blood bilirubin increased 22 217 47 286 (47.3) 0 5 0 5 (<1) 0 4 0 4 (<1)
Blood phosphorus decreased 3 30 1 34 (5.6) 4 24 1 29 (4.8) 2 35 0 37 (6.2)
Blood glucose increased 11 15 0 26 (4.3) 15 9 2 26 (4.3) 15 11 1 27 (4.5)

ATV/r= atazanavir/ritonavir, RAL= raltegravir, DRV/r = darunavir/ritonavir

For clinical adverse effects, grade 2 = moderate, grade 3 = severe, Grade 4= potentially life-threatening For blood bilirubin increased grade 2 = 1.6–2.5 x upper limit of normal (ULN), grade 3 = 2.6–5.0 x ULN, grade 4 = >5.0 x ULN. For blood phosphorous decreased, grade 2 = 0.65–0.80 mmol/L, grade 3 = 0.32–0.64 mmol/L, grade 4 = <0.32 mmol/L. For blood glucose increased, grade 2 = 8.89–13.88 mmol/L, grade 3 = 13.89–27.75 mmol/L, grade 4 = >27.75 mmol/L